Analysts Offer Predictions for CGTX Q1 Earnings

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Research analysts at B. Riley issued their Q1 2026 earnings estimates for shares of Cognition Therapeutics in a research report issued on Friday, November 21st. B. Riley analyst M. Mamtani anticipates that the company will post earnings of ($0.07) per share for the quarter. B. Riley currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.80) per share. B. Riley also issued estimates for Cognition Therapeutics’ Q2 2026 earnings at ($0.05) EPS and Q4 2026 earnings at ($0.12) EPS.

Cognition Therapeutics (NASDAQ:CGTX) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01.

CGTX has been the subject of a number of other reports. HC Wainwright reiterated a “buy” rating and issued a $3.00 price target on shares of Cognition Therapeutics in a report on Wednesday, November 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cognition Therapeutics in a research note on Tuesday, November 18th. Chardan Capital reissued a “buy” rating and set a $4.00 target price on shares of Cognition Therapeutics in a report on Friday, August 8th. Finally, Wall Street Zen raised shares of Cognition Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $3.33.

Cognition Therapeutics Stock Up 10.1%

Shares of NASDAQ CGTX opened at $1.53 on Monday. The stock’s 50 day moving average price is $1.60 and its two-hundred day moving average price is $1.17. Cognition Therapeutics has a 52-week low of $0.22 and a 52-week high of $3.83. The stock has a market capitalization of $135.05 million, a P/E ratio of -3.19 and a beta of 1.23.

Hedge Funds Weigh In On Cognition Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. CM Management LLC grew its position in shares of Cognition Therapeutics by 100.0% during the first quarter. CM Management LLC now owns 400,000 shares of the company’s stock worth $168,000 after acquiring an additional 200,000 shares during the last quarter. Northeast Financial Consultants Inc boosted its stake in Cognition Therapeutics by 158.6% during the 1st quarter. Northeast Financial Consultants Inc now owns 63,351 shares of the company’s stock valued at $27,000 after purchasing an additional 38,851 shares during the period. Acadian Asset Management LLC grew its position in Cognition Therapeutics by 814.1% in the 1st quarter. Acadian Asset Management LLC now owns 1,007,586 shares of the company’s stock worth $422,000 after purchasing an additional 897,353 shares during the last quarter. DAVENPORT & Co LLC acquired a new stake in shares of Cognition Therapeutics in the third quarter valued at approximately $3,631,000. Finally, CWA Asset Management Group LLC bought a new stake in shares of Cognition Therapeutics during the third quarter valued at approximately $34,000. Institutional investors and hedge funds own 43.35% of the company’s stock.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.